A new drug targeting atopic dermatitis has recently been approved by the FDA. EBGLYSS, from Eli Lilly, inhibits the action of a cytokine believed to be the primary driver behind the condition. Effective treatment of atopic dermatitis can significantly improve the lives of those affected, who may otherwise suffer from sleep disturbances, social stigmatization, discomfort, and social isolation. The drug is approved for adults and children 12 years or older with moderate-to-severe atopic dermatitis. This skin condition is characterized by itching, redness, swelling, and cracking of the skin, which can lead to clear or bloody fluid weeping.
Individuals with a family history of atopic dermatitis or allergies are more likely to develop the condition. It often appears during infancy or childhood but can occur at any point in life. Treatment options for atopic dermatitis include topical and other drug therapies, but finding an effective treatment can be challenging. Cytokines, particularly IL-4, IL-13, and IL-31, play key roles in the inflammation and itching associated with atopic dermatitis. EBGLYSS inhibits the production of IL-13 and has shown promising results in clinical trials, making it a valuable addition to dermatologists’ treatment options.
The approval of EBGLYSS was based on the findings of two 52-week clinical trials, ADvocate 1 and ADvocate 2, as well as the safety and efficacy evaluation in the ADhere studies. The drug is administered as an initial startup dose followed by injections every two weeks until week 16, and then as a monthly injection. A significant percentage of participants in the trials experienced clear or nearly clear skin after treatment with EBGLYSS, with the majority maintaining these results at one year with monthly dosing. Common side effects of the drug include eye and eyelid inflammation, injection site reactions, and shingles.
Atopic dermatitis can have a profound impact on quality of life, leading to constant itching, painful flare-ups, and infections. Successful treatment with drugs like EBGLYSS can significantly reduce symptoms and improve overall well-being. Patients who undergo effective treatment report a decrease in flare-ups, improved sleep quality, increased energy levels, boosted mood, and enhanced confidence. The approval of drugs like EBGLYSS provides healthcare professionals with more effective treatment options tailored to the needs of individuals with atopic dermatitis, helping them regain their confidence and improve their overall quality of life.
